



BOTOX[®]
onabotulinumtoxinA injection

11 indications

The Pediatric Spasticity Indication for BOTOX[®] Has Been Expanded

Allergan, an AbbVie Company, is excited to announce that the Pediatric Spasticity indication for BOTOX[®] has been updated to include patients with lower limb spasticity due to cerebral palsy. Now you can help **even more** Pediatric Spasticity patients get the treatment that may be right for them.

Indication Spasticity

BOTOX[®] for injection is indicated for the treatment of spasticity in patients 2 years of age and older.

Limitations of Use

BOTOX[®] has not been shown to improve upper extremity functional abilities or range of motion at a joint affected by a fixed contracture.

BOTOX[®] can now be used to treat Pediatric Lower Limb Spasticity due to cerebral palsy

This expanded use of BOTOX[®] represents the ongoing commitment of Allergan[®] to partner with physicians—like you!—who care for Pediatric Spasticity patients and bring them available treatment options.



CONTACT YOUR REPRESENTATIVE TO LEARN MORE ABOUT THIS PIVOTAL UPDATE

Thank you

for your continued dedication to and support of the Pediatric Spasticity and cerebral palsy communities.

Allergan[®] is proud to join physicians in advancing care for these important patients.

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of BOTOX[®] and all botulinum toxin product may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat Cervical Dystonia and spasticity and at lower doses.

CONTRAINDICATIONS

BOTOX[®] is contraindicated in the presence of infection at the proposed injection site(s) and in patients who are hypersensitive to any botulinum toxin product or to any of the components in the formulation.

WARNINGS AND PRECAUTIONS

Spread of Toxin Effect

See Boxed Warning.

Lack of Interchangeability Between Botulinum Toxin Products

The potency Units of BOTOX[®] are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, Units of biological activity of BOTOX[®] cannot be compared to nor converted into Units of any other botulinum toxin products assessed with any other specific assay method.

Serious Adverse Reactions With Unapproved Use

Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX[®] injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX[®] to the site of injection and/or adjacent structures. In several of the cases, patients had pre-existing dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX[®]. The safety and effectiveness of BOTOX[®] for unapproved uses have not been established.

Hypersensitivity Reactions

Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such a reaction occurs, further injection of BOTOX[®] should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent, and consequently the causal agent cannot be reliably determined.

Increased Risk of Clinically Significant Effects With Pre-existing Neuromuscular Disorders

Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis (ALS), or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored when given botulinum toxin. Patients with known or unrecognized neuromuscular disorders or neuromuscular junction disorders may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from therapeutic doses of BOTOX[®] (see *Warnings and Precautions*).

Dysphagia and Breathing Difficulties

Treatment with BOTOX[®] and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see *Boxed Warning*).

Pulmonary Effects of BOTOX[®] in Patients With Compromised Respiratory Status Treated for Spasticity

Patients with compromised respiratory status treated with BOTOX[®] for spasticity should be monitored closely.

Upper Respiratory Tract Infections in Patients Treated for Spasticity

In pediatric patients treated for upper limb spasticity, upper respiratory tract infections were reported more frequently as an adverse reaction in patients treated with BOTOX[®] (17% at 6 Units/kg and 10% at 3 Units/kg) compared to placebo (9%). In pediatric patients treated for lower limb spasticity, upper respiratory tract infection was not reported with an incidence greater than placebo.

Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

ADVERSE REACTIONS

Adverse reactions to BOTOX[®] for injection are discussed in greater detail in the following sections: *Boxed Warning*, *Contraindications*, and *Warnings and Precautions*.

Pediatric Upper Limb Spasticity

The most frequently reported adverse reactions following injection of BOTOX[®] in pediatric upper limb spasticity include upper respiratory tract infection (includes upper respiratory tract infection and viral upper respiratory tract infection), injection-site pain, nausea, constipation, rhinorrhea, nasal congestion, and seizure (includes seizure and partial seizure).

Pediatric Lower Limb Spasticity

The most frequently reported adverse reactions following injection of BOTOX[®] in pediatric lower limb spasticity include injection-site erythema, injection-site pain, oropharyngeal pain, ligament sprain, skin abrasion, and decreased appetite.

Postmarketing Experience

Adverse reactions that have been identified during postapproval use of BOTOX[®] are discussed in greater detail in Postmarketing Experience (Section 6.3 of the Prescribing Information).


There have been spontaneous reports of death, sometimes associated with dysphagia, pneumonia, and/or other significant debility or anaphylaxis, after treatment with botulinum toxin. There have also been reports of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including cardiovascular disease. The exact relationship of these events to the botulinum toxin injection has not been established.

DRUG INTERACTIONS

Co-administration of BOTOX[®] and other agents interfering with neuromuscular transmission (eg, aminoglycosides, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX[®] may potentiate systemic anticholinergic effects. The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX[®].

Please see BOTOX[®] full Prescribing Information including Boxed Warning and Medication Guide.

PS: Visit [BOTOX ACADEMY](#)[®] for the latest online training and educational resources.



Allergan
2525 Dupont Drive, Irvine, CA 92612
All trademarks are the property of their respective owners. © 2020 AbbVie. All rights reserved.
BNO138921 07/20 007114